TG Additional Data Presentations for BRIUMVI in MS at the American Academy of Neurology

  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI^® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. Links to the data presented yesterday are included below.

Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated “The data presented this week during the AAN annual meeting emphasizes our commitment to research and the multiple sclerosis community. We look forward to continuing to evaluate date from the ULTIMATE Phase 3 trials and presenting additional exploratory data throughout the year.”

https://www.biospace.com/article/releases/tg-therapeutics-announces-additional-data-presentations-for-briumvi-ublituximab-xiiy-in-multiple-sclerosis-at-the-american-academy-of-neurology-2024-annual-meeting/